Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.52 |
| ▸ | KDR | P35968 | 8/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.45 |
| ▸ | EPHB4 | P54760 | 7/20 | 0.45 |
| ▸ | EPHA2 | P29317 | 6/20 | 0.45 |
| ▸ | FLT1 | P17948 | 5/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.45 |
| ▸ | RET | P07949 | 2/20 | 0.45 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.45 |
| ▸ | EPHA4 | P54764 | 2/20 | 0.45 |
| ▸ | BTK | Q06187 | 2/20 | 0.45 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.45 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.45 |
| ▸ | STK10 | O94804 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | YES1 | P07947 | 1/20 | 0.45 |
| ▸ | LYN | P07948 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19125349 | 0.93 | KDR (0.49) | EGFRKDRERBB2EPHB4EPHA2 | |
| SCHEMBL19123892 | 0.90 | KCNH2 (0.51) | EGFRERBB2KCNH2ABCG2 | |
| SCHEMBL16212500 | 0.90 | KDR (0.57) | EGFRKDRERBB2EPHB4EPHA2 | |
| SCHEMBL17967489 | 0.88 | EGFR (0.57) | EGFRKDRERBB2EPHB4EPHA2 | |
| SCHEMBL16212779 | 0.87 | FBP1 (0.58) | EGFRKDRERBB2EPHB4EPHA2 | |
| SCHEMBL19100062 | 0.85 | EGFR (0.53) | EGFRKDRERBB2EPHB4EPHA2 | |
| SCHEMBL16212241 | 0.85 | EGFR (0.63) | EGFRKDRERBB2EPHB4EPHA2 | |
| SCHEMBL19100077 | 0.84 | FBP1 (0.52) | EGFRKDRERBB2RETKCNH2 | |
| SCHEMBL18012086 | 0.84 | EGFR (0.63) | EGFRKDRERBB2EPHB4EPHA2 | |
| SCHEMBL19125747 | 0.84 | EGFR (0.55) | EGFRKDRERBB2EPHB4EPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190016689-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2019-01-17 | — | — | US | disclosed |
| EP-3400216-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | Trillium Therapeutics Inc. (CA) | 2018-11-14 | — | — | EP | disclosed |
| WO-2017117680-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2017-07-13 | — | — | WO | disclosed |
| WO-2017117680-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2017-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016689-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | EGFR 1/4885KDR 202/4885ERBB2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.